Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

• by Shahram Salek-Ardakani

• June 2, 2026

Analysis of Health Claims Data for German Patients with Atopic Dermatitis Not Adequately Managed by Standard Systemic Treatments

• by Carolina Schwedhelm, Leonie Kunk, Dorota Pawlowska-Phelan, Olaf Behmer, Anja Plenske, Jessica Herrath, Diamant Thaçi, Agnes Kisser

• April 13, 2026

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

• by Matthew P. Kosloski, Ching-Ha Lai, Michael A. Partridge, Vanaja Kanamaluru, Ashish Bansal, Brad Shumel, Marius Ardeleanu, Hong Yan, Christine Xu, Ainara Rodríguez Marco, Jing Xiao, Faisal A. Khokhar, Guy Gherardi, Elisa Babilonia, Bolanle Akinlade, Albert Torri, John D. Davis

• April 29, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min